07:26 AM EDT, 05/14/2025 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) reported a Q1 net loss Wednesday of $0.35 per diluted share, wider than a loss of $0.11 a year earlier.

Analysts polled by FactSet expected a loss of $0.32.

Revenue for the quarter ended March 31 was $8 million.

Analysts surveyed by FactSet expected $7.5 million.

As of March 31, the company said it had $275.7 million in cash and cash equivalents on hand, and expected it could fund operations through the next three years.

ARS' shares were 1.1% higher in premarket trading.